Patent US4954487A successfully refreshed from Google Patents.
US4954487A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Penetrating topical pharmaceutical compositions
Assignee: Procter and Gamble Co
•
Filing: 1989-02-15
•
Granted: 1990-09-04
•
Expires: 2009-02-15
Abstract
Abstract A large group of lipophilic, pharmacologically active compounds can be effectively delivered across intact skin by applying them topically in a binary, penetration-enhancing vehicle containing (1) a C3-C4 diol, diol ester, or diol ether and (2) a cell envelope-disordering compound. This vehicle provides surprising enhancement of skin penetration for the pharmacological active, compared to either component alone.
Inventors
- 👤 Eugene R. Cooper
- 👤 Maurice E. Loomans
- 👤 Richard R. Wickett
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 23:24
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/14
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
123 words
A composition of matter for topical administration, said composition comprising (a) from about 0.5% to about 35% by weight of a nonsteroidal anti-inflammatory agent selected from the group consisting of salicylic acid, ibuprofen, sulindac, naproxen, ketoprofen, ethofenamate, and indomethacin, and the pharmaceutically-acceptable salts and esters thereof; (b) from 0% to about 70% by weight ethanol or 2-propanol; and (c) a penetration-enhancing carrier consisting essentially of (i) from about 10% to about 98% by weight of the composition of propylene glycol; and (ii) from about 1% to about 5% by weight of the composition of a cell envelope-disordering compound selected from the group consisting of methyl myristate, methyl laurate, methyl caprate, ethyl myristate, ethyl laurate, ethyl caprate, myristyl acetate, lauryl acetate and capric acetate.
Claim 2
Dependent Claim
123 words
A composition of matter for topical administration, said composition comprising (a) from about 0.5% to about 35% by weight of a nonsteroidal anti-inflammatory agent selected from the group consisting of salicylic acid, ibuprofen, sulindac, naproxen, ketoprofen, ethofenamate, and indomethacin, and the pharmaceutically-acceptable salts and esters thereof; (b) from 0% to about 70% by weight ethanol or 2-propanol; and (c) a penetration-enhancing carrier consisting essentially of (i) from about 10% to about 98% by weight of the composition of propylene glycol; and (ii) from about 1% to about 5% by weight of the composition of a cell envelope-disordering compound selected from the group consisting of methyl myristate, methyl laurate, methyl caprate, ethyl myristate, ethyl laurate, ethyl caprate, myristyl acetate, lauryl acetate and capric acetate.
Claim 3
Dependent Claim
30 words
The composition of claim 1 wherein the cell-envelope disordering compound is selected from the group consisting of methyl myristate, methyl laurate, ethyl myristate, ethyl laurate, myristyl acetate and lauryl acetate.
Claim 4
Dependent Claim
12 words
The composition of claim 1 wherein the nonsteroidal anti-inflammatory agent is ibuprofen.
Claim 5
Dependent Claim
12 words
The composition of claim 1 wherein the nonsteroidal anti-inflammatory agent is naproxen.
Claim 6
Dependent Claim
12 words
The composition of claim 1 wherein the nonsteroidal anti-inflammatory agent is ketoprofen.
Claim 7
Dependent Claim
13 words
The composition of claim 1 wherein the cell-envelope disordering compound is methyl laurate.
Claim 8
Dependent Claim
24 words
The composition of any of claim 1-6 wherein the concentration of the nonsteroidal anti-inflammatory agent is from about 1% to saturation in the composition.
Claim 9
Independent Claim
45 words
A method for treating and preventing pain or inflammation in a human or lower animal, which method comprises applying topically to a human or lower animal in need of such treatment a safe and effective amount of a composition according to any of claims 1-6.
References Cited (Backward Citations)
US2990331A
Cited
GB1133800A
Cited
US3535422A
Cited
US3592930A
Cited
US3888995A
Cited
US3924004A
Cited
US4006218A
Cited
DE2514873A1
Cited
US4126681A
Cited
US4075353A
Cited
US4070462A
Cited
CA1072009A
Cited
GB1594314A
Cited
US4309414A
Cited
US4299826A
Cited
US4537776A
Cited
US4552872A
Cited
US4557934A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-09-03 | 1994-03-05 | 1994-09-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-09-03 | 1998-03-05 | 1998-09-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-09-03 | 2002-03-05 | 2002-09-04 | $7700.00 | Window Closed / Lapsed |